OliPass Corporation

[Not Yet Scheduled]
OliPass is a clinical stage biotech company based in South Korea . The company is developing the next generation antisense medicines based on its proprietary OPNA (Olipass Peptide Nucleic Acids) platform technology. The platform technology uses covalently modified peptide nucleic acid molecules to improve cell permeability. The antisense drug candidates developed by OliPass are expected to have the high safety margin by very low clinical dose, wide range of disease applications with flexible ROA by improved tissue distribution without requiring special formulation, and affordable to patients by simple synthetic process and low therapeutic dose that leads to low cost of goods.
Ticker:
244460
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
OLP-1002 for Pain
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5